Epicutaneous immunotherapy: A review of safety and efficacy DOI
Aikaterini Anagnostou, Matthew Greenhawt

Pediatric Allergy and Immunology, Год журнала: 2025, Номер 36(4)

Опубликована: Апрель 1, 2025

Abstract Epcutaneous immunotherapy (EPIT) is a novel, non‐oral route of allergen immunotherapy, utilizing the skin and its robust density epidermal Langerhans cells (LC) for antigen presentation. This space non‐vascularized impermeable, which limits exposure into bloodstream but preserves presentation to regional lymph nodes generate gut‐homing regulatory T cells. The EPIT patch utilizes natural water loss from absorb electrosprayed through condensation. represents an alternative, food allergy, with good efficacy strong safety profiles across multiple phase 2 3 studies milk peanut. Efficacy appears best in very young children (1–3 years old), has been shown continue enhance extended treatment duration up 36 months. slightly older ages 4–11 age less clear, be better 4–7 age. In clinical trials peanut EPIT, most subjects experienced adverse effects, mainly mild‐to‐moderate reactions localized around placement site, improve continued wear. Rates treatment‐related anaphylaxis have low all ages, ranging 1.6% 4%, were lowest infant toddler population. While further (1‐ 3‐year‐olds) (4‐ 7‐year‐olds) are ongoing, potentially valuable addition current landscape allergy therapies, particular infants toddlers where families may seeking treatment. image

Язык: Английский

Immune therapies in coeliac disease and food allergies: Advances, challenges, and opportunities DOI Creative Commons
Dianne E. Campbell, Sam Mehr, Olivia Moscatelli

и другие.

Seminars in Immunology, Год журнала: 2025, Номер 78, С. 101960 - 101960

Опубликована: Апрель 23, 2025

Coeliac disease and food allergy management primarily relies on the strict avoidance of dietary antigens. This approach is challenging to maintain in real-world settings carries risk life-threatening anaphylaxis. Despite their distinct pathogenesis, both disorders are driven by maladaptive responses proteins, creating opportunities for shared treatment strategies. In allergy, desensitisation therapies such as oral, sublingual, epicutaneous immunotherapy well-established, complemented biologics like omalizumab dupilumab. However, induction sustained tolerance remains challenging. contrast, therapeutic advancements coeliac still early stages. Current efforts focus gluten detoxification or modification, immune blockade modulation, tolerogenic approaches, barrier restoration. Emerging therapies, including JAK BTK inhibitors microbiome-targeted interventions, support further targeted options conditions. Biomarkers tracking gluten-specific T cells have emerged valuable tools immunomonitoring symptom assessment disease, although standardisation patient-reported outcome measures challenge protocols needed. Food trials reliant double-blind placebo-controlled challenges measure allergen reactivity, but these time-consuming, carry risks, underscore need surrogate biomarkers. The successful development immune-targeted will require building an toolset optimally assess systemic antigens Clinically, this could lead better outcomes patients who might otherwise remain undiagnosed untreated due absence significant enteropathy allergen-specific symptoms.

Язык: Английский

Процитировано

0
Epicutaneous immunotherapy: A review of safety and efficacy DOI
Aikaterini Anagnostou, Matthew Greenhawt

Pediatric Allergy and Immunology, Год журнала: 2025, Номер 36(4)

Опубликована: Апрель 1, 2025

Abstract Epcutaneous immunotherapy (EPIT) is a novel, non‐oral route of allergen immunotherapy, utilizing the skin and its robust density epidermal Langerhans cells (LC) for antigen presentation. This space non‐vascularized impermeable, which limits exposure into bloodstream but preserves presentation to regional lymph nodes generate gut‐homing regulatory T cells. The EPIT patch utilizes natural water loss from absorb electrosprayed through condensation. represents an alternative, food allergy, with good efficacy strong safety profiles across multiple phase 2 3 studies milk peanut. Efficacy appears best in very young children (1–3 years old), has been shown continue enhance extended treatment duration up 36 months. slightly older ages 4–11 age less clear, be better 4–7 age. In clinical trials peanut EPIT, most subjects experienced adverse effects, mainly mild‐to‐moderate reactions localized around placement site, improve continued wear. Rates treatment‐related anaphylaxis have low all ages, ranging 1.6% 4%, were lowest infant toddler population. While further (1‐ 3‐year‐olds) (4‐ 7‐year‐olds) are ongoing, potentially valuable addition current landscape allergy therapies, particular infants toddlers where families may seeking treatment. image

Язык: Английский

Процитировано

0